Major therapeutic advances and new perspectives in onco-hematology

被引：7
作者：
Bay, Jacques-Olivier [1 ,2 ]
Guieze, Romain [1 ,2 ]
Ravinet, Aurelie [1 ]
Lemal, Richard [1 ]
Xhaard, Alienor [3 ]
Bailly, Sebastien [1 ]
Molucon-Chabrot, Cecile [1 ]
Hermet, Eric [1 ]
Biau, Julian [4 ]
Verrelle, Pierre [4 ]
de latour, Regis Peffault [3 ]
Tournilhac, Olivier [1 ,2 ]
机构：
[1] CHU Clermont Ferrand, Serv Hematol Clin Adulte & Therapie Cellulaire, F-63003 Clermont Ferrand 01, France
[2] Univ Auvergne, EA7283, CIC501, F-63000 Clermont Ferrand, France
[3] Hop St Louis, Serv Hematol Greffe, F-75010 Paris, France
[4] Ctr Jean Perrin, Serv Radiotherapie, F-63000 Clermont Ferrand, France
来源：
BULLETIN DU CANCER | 2013年 / 100卷 / 06期
关键词：
cancer; chemotherapy; targeted therapies; allo-graft; perspective; retrospective; CHRONIC LYMPHOCYTIC-LEUKEMIA; EXTENDED-FIELD RADIOTHERAPY; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HODGKINS-LYMPHOMA; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; BODY IRRADIATION;
D O I：
10.1684/bdc.2013.1751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hematology Oncology has a rich history including few crucial therapeutic innovations. These were possible because of the evolution of the cell and molecular biology allowing a better understanding of basic mechanisms of cancerogenesis. We propose here to summarize the most important therapeutic innovations since the beginning of Hematology/Oncology history. We also describe evolution of therapeutic strategies themselves. New insights and therapeutic perspectives for next future are also discussed.
引用
收藏
页码：587 / 599
页数：13
相关论文
共 92 条
  • [1] TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS
    ALEXANIAN, R
    HAUT, A
    KHAN, AU
    LANE, M
    MCKELVEY, EM
    MIGLIORE, PJ
    STUCKEY, WJ
    WILSON, HE
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) : 1680 - +
  • [2] Andre MP, 2009, ASH ANN M, V114, P97
  • [3] NEUROPHARMACOLOGY OF EMESIS INDUCED BY ANTI-CANCER THERAPY
    ANDREWS, PLR
    RAPEPORT, WG
    SANGER, GJ
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (09) : 334 - 341
  • [4] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wang, Xuemei
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Lerner, Susan
    Kantarjian, Hagop
    Wierda, William G.
    [J]. BLOOD, 2011, 118 (08) : 2085 - 2093
  • [5] TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW - PRELIMINARY COMMUNICATION
    BARNES, DWH
    CORP, MJ
    LOUTIT, JF
    NEAL, FE
    [J]. BRITISH MEDICAL JOURNAL, 1956, 2 (SEP15) : 626 - 627
  • [6] BERNARD J, 1959, Schweiz Med Wochenschr, V89, P604
  • [7] BERNARD J, 1972, NOUV PRESSE MED, V1, P2149
  • [8] ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF TREATMENT BY DAUNORUBICIN
    BERNARD, J
    WEIL, M
    BOIRON, M
    JACQUILLAT, C
    FLANDRIN, G
    GEMON, MF
    [J]. BLOOD, 1973, 41 (04) : 489 - 496
  • [9] STRATEGIES IN PREVENTION OF INVASIVE PULMONARY ASPERGILLOSIS IN IMMUNOSUPPRESSED OR NEUTROPENIC PATIENTS
    BEYER, J
    SCHWARTZ, S
    HEINEMANN, V
    SIEGERT, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) : 911 - 917
  • [10] BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
12345678910